Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients.
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to undertake a phase 1 trial of I-ATT001, its Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma.
Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript November 17, 2023 Operator: Good morning. My name is Alan, and I will be your operator today. At this time I would like to welcome you to Imunon’s Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] I would like now to turn the call over to […]